Here’s why these four pharma stocks are in focus today
Caplin Point
The US Food and Drug Administration (USFDA) has issued 10 observations to Caplin Point Laboratories‘ sterile and ophthalmic manufacturing facility in Gummidipoondi.
The US drug regulator had conducted an unannounced inspection from August 13 to August 31.
Caplin Point said the observations are procedural in nature and it will address the same comprehensively and respond.
Shares of Caplin Point Laboratories ended the previous session 1.6% up at ₹2,569.7 apiece. The stock has risen 4.2% in the past month and is up 42.9% this year, so far.
Aurobindo Pharma
The USFDA conducted routine inspections at the company’s peptide API facility in Telangana and issued one observation.
Corrective action was initiated during the course of inspection.
Shares of Aurobindo Pharma ended the previous session 0.4% up at ₹1,614.9 apiece The stock has gained 5.4% in the past month and is up 35.4% this year, so far.Natco Pharma
The USFDA inspected Natco Pharma‘s formulation unit at Vishakapatnam plant. The US drug regulator has issued four observations towards it.
Shares of Natco Pharma ended the previous session 0.6% up at ₹882.6 apiece. The stock has declined 4.2% in the past month and is down 0.6% this year, so far.
Jubilant Pharmova
The USFDA gave its approval to the company’s US arm Jubilant HillisterStier for the contract manufacture of first batch of product on Line 3, a new isolator-based fill-and-finish line, at its manufacturing facility in Spokane, Washington D.C.
Shares of Jubilant Pharmova ended the previous session 0.7% up at ₹877 apiece. The stock has declined 9.2% in the past month and is down 17.1% this year, so far.
Also Read: Skyways Air Services IPO opens August 24: Should you subscribe or avoid the ₹583 crore issue?
